Oncotarget

Research Papers:

miR-382 inhibits tumor growth and enhance chemosensitivity in osteosarcoma

Meng Xu _, Hua Jin, Cheng-Xiong Xu, Bo Sun, Zhi Mao, Wen-Zhi Bi and Yan Wang

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2014; 5:9472-9483. https://doi.org/10.18632/oncotarget.2418

Metrics: PDF 2598 views  |   HTML 2621 views  |   ?  


Abstract

Meng Xu1, Hua Jin2, Cheng-Xiong Xu3, Bo Sun4, Zhi Mao1, Wen-Zhi Bi1, Yan Wang1

1 Department of Orthopaedics, The General Hospital of Chinese People's Liberation Army, Beijing, China.

2 Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA.

3 Departments of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

4 State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.

Correspondence to:

Dr. Cheng-Xiong Xu, e-mail: [email protected]

Yan Wang, e-mail: [email protected]

Keywords: miR-382, osteosarcoma growth, chemoresistance

Received: July 11, 2014     Accepted: August 28, 2014     Published: September 05, 2014

ABSTRACT

Dysregulation of miRNAs is involved in osteosarcoma (OS). Here, we demonstrate that miR-382 is decreased in specimens of OS patients with a poor chemoresponse compared to those with a good chemoresponse. In addition, our clinical data show that decreased miR-382 was associated with poor survival in OS patients. Overexpression of miR-382 inhibited cell growth and chemoresistance by targeting KLF12 and HIPK3, respectively. In contrast, inhibition of miR-382 or overexpression of target genes stimulated OS cell growth and chemoresistance both in vitro and in vivo. Taken together, these findings suggest that miR-382 is a tumor suppressor miRNA and induction of miR-382 is a potential strategy to inhibit OS progression.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2418